\u00a0S&P\/ASX 200 Health Care closed flat in May
\n2024 brings challenges, but hopes are high for biotech stocks
\nWe take a look at the ASX biotech winners for the month<\/p>\n
\u00a0<\/p>\n
The \u00a0S&P\/ASX 200 Health Care [XHJ]<\/strong> closed flattish for the month of May.<\/p>\n With half the year almost over, 2024 is so far shaping up to be a year of both challenges and exciting opportunities.<\/p>\n As investors and industry experts chart their course through this dynamic landscape, one thing is clear: science remains at the forefront of it all.<\/p>\n Stephanie Sirota<\/strong>, chief business officer of RTW Investments<\/strong>, shares her perspective on what lies ahead for biotech stocks.<\/p>\n For Sirota and her team, the journey in discovering biotech stocks with potential begins with a deep dive into the science behind each company.<\/p>\n First and foremost, Sirota says that she aims to seek out medical innovations with the potential to make a real difference, focusing on long-term value rather than short-lived gains.<\/p>\n \u201cI would say that our favourite investment is where we identify an asset that we believe is going to have a meaningful transformational effect, not just a short-term momentum-driven step up,\u201d said Sirota.<\/p>\n \u201cWe\u2019re looking for stocks where we can get multiples of return, because we\u2019re identifying value before the rest of the market has identified that.<\/p>\n \u201cWe really look for drugs that we think are going to be placing and disrupting that current standard of care or bringing a new standard of care,\u201d she added.<\/p>\n But navigating the market isn\u2019t without its hurdles.<\/p>\n Funding can be hard to come by, especially during market downturns.<\/p>\n \u201c..When you have a market downturn, the competition for capital is fierce,\u201d Sirota said.<\/p>\n Her strategy? Steering clear of crowded areas and backing ventures poised to disrupt the status quo.<\/p>\n Yet, amidst the challenges, there\u2019s reason for optimism.<\/p>\n Mergers and acquisitions in the biotech space are on the rise, signalling a new era of collaboration between biotech firms and industry giants.<\/p>\n \u201c\u2026At some point, the large companies, whether it\u2019s big pharma or large biotech, they have the ability to sell a drug and to properly commercialise it and to take those approved therapies and bring them to global markets.<\/p>\n \u201cA biotech company, particularly a small or even a mid-sized biotech company, doesn\u2019t always have the capability of doing it on its own,\u201d Sirota noted.<\/p>\n Meanwhile, the IPO market has seen a flurry of activity this year, albeit with a cautious approach from investors.<\/p>\n Companies are treading carefully, opting to go public only when they\u2019re confident in their ability to deliver results.<\/p>\n But perhaps the most exciting development of all is the wave of positive clinical data sweeping through the industry.<\/p>\n Breakthroughs in research are fuelling optimism, and with the US FDA adopting a more favourable stance towards innovation, the path to regulatory approval has never looked more promising.<\/p>\n \u201cHopefully, with a wave of positive clinical data from biotech companies, and then also a stable or hopefully a lower interest rate environment, all that capital is going to come crashing back,\u201d Sirota said.<\/p>\n \u00a0<\/p>\n Code Name Price % Month Change Market Cap LTP LTR Pharma 0.605 133% $42,595,320 BDX Bcal Diagnostics 0.175 90% $44,151,575 CU6 Clarity Pharma 5.080 81% $1,579,950,104 CYP Cynata Therapeutics 0.335 60% $60,176,648 DXB Dimerix 0.495 48% $272,088,943 MDR Medadvisor 0.440 47% $242,144,446 VTI Vision Tech Inc 0.160 45% $8,805,835 COV Cleo Diagnostics 0.250 35% $18,525,000 TD1 Tali Digital 0.002 33% $6,590,311 BOT Botanix Pharma 0.290 32% $456,789,815 AGN Argenica 0.770 32% $94,569,664 SOM SomnoMed 0.280 30% $60,510,311 OIL Optiscan Imaging 0.115 29% $96,064,192 BMT Beamtree Holdings 0.230 28% $66,465,643 ILA Island Pharma 0.067 26% $7,673,948 CTE Cryosite 1.070 26% $52,226,232 SNT Syntara 0.020 25% $23,880,636 PGC Paragon Care 0.390 22% $260,468,590 TLX Telix Pharmaceutical 18.150 21% $5,259,157,375 NC6 Nanollose 0.024 20% $4,128,153 EZZ EZZ Life Science 1.065 20% $47,300,058 NOX Noxopharm 0.080 19% $23,379,036 PEB Pacific Edge 0.090 18% $73,014,421 ACR Acrux 0.081 17% $23,548,065 PER Percheron 0.081 17% $73,025,143 EBR EBR Systems 1.100 17% $338,899,284 EMD Emyria 0.059 16% $24,130,374 ARX Aroa Biosurgery 0.570 14% $196,198,465 EOF Ecofibre 0.068 13% $25,763,425 ATX Amplia Therapeutics 0.070 13% $19,012,646 NEU Neuren Pharmaceut. 21.640 13% $2,645,854,407 MSB Mesoblast 1.110 12% $1,267,380,367 AVH Avita Medical 2.990 11% $185,928,127 1AI Algorae Pharma 0.011 10% $18,561,342 PNV Polynovo 2.250 10% $1,518,512,052 MAP Microbalifesciences 0.200 10% $89,570,395 CDX Cardiex 0.058 9% $17,062,125 ONE Oneview Healthcare 0.320 8% $215,996,048 PYC PYC Therapeutics 0.105 8% $489,938,758 PME Pro Medicus 120.120 8% $12,538,295,582 ALC Alcidion Group 0.058 7% $77,863,447 CUV Clinuvel Pharmaceut. 15.900 6% $758,571,002 PBP Probiotec 3.030 6% $246,409,920 HLS Healius 1.270 5% $922,146,928 FPH Fisher & Paykel H. 27.200 5% $15,434,583,365 IDT IDT Australia 0.100 5% $35,147,947 SHG Singular Health 0.105 5% $20,538,321 IMM Immutep 0.450 5% $534,975,552 TRI Trivarx 0.027 4% $10,650,885 VLS Vita Life Sciences.. 2.250 4% $125,423,568 DOC Doctor Care Anywhere 0.065 3% $23,831,746 HMD Heramed 0.018 3% $7,078,497 CAJ Capitol Health 0.245 2% $261,181,637 NSB Neuroscientific 0.049 2% $7,085,639 PSQ Pacific Smiles Grp 1.900 2% $303,205,682 IBX Imagion Biosys 0.074 1% $2,383,198 CSL CSL 280.100 1% $134,498,899,535 REG Regis Healthcare 3.970 1% $1,180,056,882 AFP Aft Pharmaceuticals 2.800 0% $293,625,528 AMT Allegra Medical 0.029 0% $3,468,720 CAN Cann Group 0.062 0% $27,123,891 HGV Hygrovest 0.046 0% $9,674,288 IVX Invion 0.005 0% $32,122,661 MX1 Micro-X 0.092 0% $53,462,095 MEM Memphasys 0.009 0% $12,309,680 MDC Medlab Clinical 6.600 0% $15,071,113 EPN Epsilon Healthcare 0.024 0% $7,208,496 DVL Dorsavi 0.013 0% $7,756,601 CBL Control Bionics 0.043 0% $8,569,331 OSL Oncosil Medical 0.005 0% $16,660,548 LGP Little Green Pharma 0.130 0% $39,228,879 IXC Invex Ther 0.080 0% $6,012,308 AHI Advanced Health 0.092 0% $22,600,111 COH Cochlear 322.560 -1% $20,952,891,987 SIG Sigma Health 1.255 -1% $2,023,514,007 4DX 4Dmedical 0.590 -2% $230,919,902 EBO Ebos Group 31.140 -2% $6,307,255,876 IMR Imricor Med Sys 0.485 -2% $98,391,015 ANR Anatara Ls 0.047 -2% $8,983,755 OCA Oceania Healthc 0.525 -3% $381,872,675 UBI Universal Biosensors 0.145 -3% $43,219,778 PCK Painchek 0.029 -3% $47,439,046 NAN Nanosonics 2.810 -4% $824,102,834 IDX Integral Diagnostics 2.440 -4% $552,150,313 ALA Arovella Therapeutic 0.120 -4% $126,018,748 GLH Global Health 0.115 -4% $6,385,449 RMD ResMed Inc. 31.400 -4% $19,882,547,249 ANN Ansell 24.450 -4% $3,555,195,450 PAA Pharmaust 0.210 -5% $83,141,359 FRE Firebrickpharma 0.060 -5% $12,304,324 OCC Orthocell 0.365 -5% $76,404,289 BIT Biotron 0.054 -5% $48,722,877 CVB Curvebeam Ai 0.180 -5% $39,344,290 ACL Au Clinical Labs 2.290 -6% $452,108,194 FCG Freedomcaregrouphold 0.160 -6% $3,821,425 IMC Immuron 0.094 -6% $21,431,845 IRX Inhalerx 0.030 -6% $5,693,009 AT1 Atomo Diagnostics 0.030 -6% $19,176,069 IIQ Inoviq 0.465 -7% $42,788,696 PAR Paradigm Bio. 0.250 -7% $87,449,004 AHC Austco Healthcare 0.180 -7% $64,938,305 CMP Compumedics 0.240 -8% $42,519,108 TRP Tissue Repair 0.230 -8% $13,302,265 SPL Starpharma Holdings 0.115 -8% $47,384,671 SDI SDI 0.790 -9% $93,903,769 HXL Hexima 0.010 -9% $1,670,396 GTG Genetic Technologies 0.100 -9% $13,221,725 SHL Sonic Healthcare 24.330 -9% $11,529,695,352 IPD Impedimed 0.076 -10% $153,755,138 RGT Argent Biopharma 0.370 -10% $16,753,675 RHC Ramsay Health Care 47.110 -10% $10,768,592,196 M7T Mach7 Tech 0.655 -10% $158,012,886 MVP Medical Developments 0.425 -11% $36,679,718 RCE Recce Pharmaceutical 0.585 -11% $119,332,538 HIQ Hitiq 0.023 -12% $8,092,434 CGS Cogstate 1.240 -12% $211,765,732 EYE Nova EYE Medical 0.245 -13% $56,061,702 RSH Respiri 0.028 -13% $28,616,461 AHX Apiam Animal Health 0.350 -13% $63,503,690 SNZ Summerset Grp Hldgs 9.160 -13% $2,158,224,029 TRJ Trajan Group Holding 0.930 -13% $141,560,959 AVR Anteris Technologies 19.000 -13% $365,224,004 CTQ Careteq 0.013 -13% $3,062,115 RHY Rhythm Biosciences 0.071 -13% $17,650,369 PTX Prescient 0.045 -13% $36,239,391 EMV Emvision Medical 1.885 -14% $161,025,906 1AD Adalta 0.025 -14% $13,372,579 ECS ECS Botanics Holding 0.018 -14% $23,193,892 CSX Cleanspace Holdings 0.280 -15% $21,654,487 IME Imexhs 0.480 -16% $21,857,712 NXS Next Science 0.260 -16% $75,840,727 ATH Alterity Therap 0.005 -17% $26,225,577 ICR Intelicare Holdings 0.010 -17% $2,348,245 OPT Opthea 0.510 -18% $338,032,403 CYC Cyclopharm 1.435 -18% $155,373,587 AYA Artrya 0.265 -20% $20,856,558 BP8DD Bph Global 0.004 -20% $1,563,293 NTI Neurotech Intl 0.071 -21% $72,234,590 RHT Resonance Health 0.064 -22% $28,601,147 PAB Patrys 0.007 -22% $14,402,131 ACW Actinogen Medical 0.029 -23% $73,280,717 IMU Imugene 0.067 -23% $490,427,477 ADR Adherium 0.016 -24% $11,681,279 CMB Cambium Bio 0.006 -25% $4,596,554 AVE Avecho Biotech 0.003 -25% $9,507,891 LDX Lumos Diagnostics 0.037 -26% $17,808,355 RAD Radiopharm 0.032 -27% $14,731,746 MYX Mayne Pharma 5.040 -28% $427,072,926 VFX Visionflex Group 0.005 -29% $7,084,956 LBT LBT Innovations 0.014 -30% $18,773,382 UCM Uscom 0.021 -30% $5,136,340 ZLD Zelira Therapeutics 0.470 -31% $5,333,163 ZLD Zelira Therapeutics 0.470 -31% $5,333,163 VIT Vitura Health 0.081 -33% $46,645,777 NYR Nyrada Inc. 0.057 -39% $10,226,296 CHM Chimeric Therapeutic 0.018 -40% $15,415,319 VBS Vectus Biosystems 0.130 -48% $6,917,368 ME1 Melodiol Glb Health 0.002 -50% $1,646,275 ENL Enlitic Inc. 0.250 -58% $19,678,657 JTL Jayex Technology 0.001 -80% $281,279 OSX Osteopore 0.053 -85% $6,020,959 <\/p>\n WordPress Table Plugin<\/a><\/p>\n \u00a0<\/p>\n LTR Pharma (ASX:LTP)<\/a><\/strong><\/p>\n LTR Pharma rose in May on no specific news.<\/p>\n However the company\u2019s shares have been rising after announcing in late March that all patients recruited for its pivotal bio-equivalence clinical study of SPONTAN nasal spray received their second and final dose, completing the recruitment and dosing stage of the clinical study.<\/p>\n SPONTAN is a unique nasal delivery technology that bypasses the digestive system and is designed to overcome the issues of oral tablets for ED (erectile dysfunction). The study is a critical milestone in LTR\u2019s path to commercialisation. Data collected from the study will used to support the pre-submission meetings with the FDA and prescriptions of SPONTAN via the early access scheme in Australia.<\/p>\n \u00a0<\/p>\n BCAL Diagnostics (ASX:BDX)<\/a><\/strong><\/p>\n BCAL recently announced some exciting news regarding its commercialisation efforts.<\/p>\n The company is gearing up to launch its new tests, and to make sure everything goes smoothly, it has brought on board a new CEO, Shane Ryan.<\/p>\n Ryan\u2019s appointment comes at a pivotal time as the company prepares to launch its new tests and accelerate its commercialisation efforts.<\/p>\n With his prior experience as the COO and a strong track record in biotechnology product commercialisation, gained from his tenure at GenesisCare, BCAL believes that Ryan is well-positioned to lead BCAL through this critical phase.<\/p>\n \u00a0<\/p>\n Clarity Pharma (ASX:CU6)<\/a><\/strong><\/p>\n Clarity has signed a Supply Agreement with SpectronRx for Cu-64 production.<\/p>\n This adds a new Cu-64 manufacturer to Clarity\u2019s network, addressing supply constraints and benefiting patients, especially in the US oncology market.<\/p>\n Cu-64\u2019s longer half-life overcomes limitations of other isotopes, providing broader access to PET imaging for cancer diagnosis.<\/p>\n \u00a0<\/p>\n Cynata Therapeutics(ASX: CYP)<\/a><\/strong><\/p>\n Cynata has published new data in a top medical journal about its treatment, CYP-001, for a serious condition called steroid-resistant acute graft versus host disease (SR-aGvHD).<\/p>\n Graft versus host disease (GvHD) is a dangerous complication that can happen after bone marrow transplants, where the transplanted immune cells attack the recipient\u2019s body. SR-aGvHD is even more challenging because it doesn\u2019t respond to standard steroid treatment.<\/p>\n The published study followed patients for two years after receiving CYP-001 treatment.<\/p>\n The results are promising: 60% of patients survived, with no serious side effects related to the treatment. This survival rate is much better than what\u2019s been seen before in similar cases.<\/p>\n For comparison, other treatments like ruxolitinib only had survival rates of around 38% after 18 months.<\/p>\n This is significant progress in treating a condition that has historically had very poor outcomes.<\/p>\n \u00a0<\/p>\n Dimerix (ASX:DXB)\u00a0<\/a><\/strong><\/p>\n Dimerix says Taiba has acquired the exclusive rights to register and commercialise DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in the United Arab Emirates (UAE), Saudi Arabia, Oman,\u00a0 Kuwait,\u00a0 Qatar,\u00a0 Bahrain\u00a0 and\u00a0 Iraq.<\/p>\n Under the deal DXB will receive up to US$80.4m (~$120.5m) from Taiba in upfront and milestone payments on certain development and sales milestones being achieved.<\/p>\n The company will also receive tiered royalties starting at 30% on net sales.<\/p>\n Taiba also has a right to negotiate a licence to develop and commercialise DMX-200 in any additional indications in the licensed territories that DXB may achieve for DMX-200. The minimum term for the deal is 15 years, or until the last valid patent claim covering the product expires.<\/p>\n DXB retains all rights to commercialise DMX-200 in all other unlicensed territories, including the US and China.<\/p>\n \u00a0<\/p>\n At Stockhead we tell it like it is. While Dimerix and LTR Pharma are Stockhead advertisers, they did not sponsor this article.\u00a0<\/em><\/p>\n <\/span><\/p>\n The post ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year<\/a> appeared first on Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"Here are the ASX Biotech Winners and Losers for May 2024<\/h2>\n
\nThe spray works by having a significantly faster onset of action of just 10 minutes.<\/p>\n